Sanofi announced positive results from the pivotal Phase 3 LIBERTY-AFRS-AIMS trial showing Dupixent significantly improved outcomes for adults and children aged 6 years and older with allergic fungal ...

Now, it’s worth noting Stock Advisor’s total average return is 1,062% — a market-crushing outperformance compared to 194 % ...

Most patients with chronic rhinosinusitis with nasal polyps no longer used oral corticosteroids after using dupilumab, ...

May 23, 2025 -- The FDA has approved the asthma drug Nucala for adults with chronic obstructive pulmonary disease (COPD). It is the second biologic therapy approved for the condition, following the ...

For the primary endpoint, Eczema Area and Severity Index (EASI) improved by 53-61% in a dose-dependent manner across the ...

COVID-19 mRNA vaccination is associated with a reduced incidence of multiple infections and allergic complications.

Sanofi and Regeneron’s Dupixent (dupilumab) could be set for its ninth US approval after the drug met all the primary and ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

In patients with moderate-to-severe allergic asthma, tezepelumab yields the greatest reduction in exacerbations among ...

Sanofi & Regeneron’s Dupixent pivotal study meets all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis: Paris Monday, November 10, ...

Sertraline (Zoloft) may relieve emotional symptoms of depression and anxiety within two weeks, while physical side effects stabilize later. The research highlights how antidepressants can act on ...

The condition, which most often affects people in warm, humid climates where fungal spores are common, can trigger nasal ...